Fibrocell awarded $1.4 million FDA Orphan grant for FCX-007 for treatment of RDEB
Fibrocell Science announced the FDA has awarded a $1.4 million clinical trial research grant for Fibrocell’s continued clinical development of FCX-007, the Company’s gene therapy candidate for treatment of recessive dystrophic epidermolysis bullosa. September 25, 2018